Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 4/2014

01-03-2014 | Adis Drug Evaluation

QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease

Author: James E. Frampton

Published in: Drugs | Issue 4/2014

Login to get access

Abstract

QVA149 (indacaterol/glycopyrronium) [Xoterna® Breezhaler®, Ultibro® Breezhaler®] is an inhaled fixed-dose combination of indacaterol (a long-acting selective β2-adrenergic receptor agonist [LABA]) and glycopyrronium (a long-acting muscarinic receptor antagonist [LAMA]) that has been approved in the EU and Japan for the symptomatic control of chronic obstructive pulmonary disease (COPD) in adults. In phase III studies, QVA149 significantly improved bronchodilation versus indacaterol, glycopyrronium or tiotropium alone and the LABA/inhaled corticosteroid fixed-dose combination salmeterol/fluticasone. These improvements in lung function, which were rapid in onset and maintained during long-term treatment, were generally associated with significant improvements in dyspnoea, health status, COPD exacerbation risk, patient symptoms, and rescue medication use. The SHINE and ILLUMINATE studies in low (exacerbation) risk patients with moderate to severe disease suggest that QVA149 may offer more symptomatic relief than tiotropium and salmeterol/fluticasone. Similarly, the SPARK study in high (exacerbation) risk patients with severe or very severe disease showed that QVA149 was more effective than glycopyrronium in preventing moderate to severe exacerbations, and suggests that QVA149 may offer more symptomatic relief than LAMA monotherapy. Another phase III study comparing QVA149 with salmeterol/fluticasone in high-risk patients with moderate to very severe disease (FLAME) is ongoing. QVA149 is generally well tolerated, with no new safety signals identified compared with its monocomponents. Bronchodilators remain central to the symptomatic management of COPD. When dual bronchodilation is indicated, QVA149 offers the convenience of two bronchodilators in a single inhaler coupled with a simple, once-daily dosing regimen that may encourage better treatment adherence. Therefore, it is a valuable option in the treatment of COPD.
Literature
1.
McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72(4):543–63.CrossRefPubMed
2.
Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741–53.CrossRefPubMed
3.
4.
5.
6.
Dahl R, Dalal J, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J COPD. 2013;8:501–8.CrossRef
7.
Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–62.CrossRefPubMed
8.
Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–9.CrossRefPubMed
9.
10.
Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273–9.CrossRefPubMed
11.
Korn S, Kerwin E, Atis S, et al. Indacaterol once daily provides superior efficacy to salmeterol twice daily in COPD: a 12-week study. Respir Med. 2011;105(5):719–26.CrossRefPubMed
12.
Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797–803.CrossRefPubMed
13.
DeCramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–33.
14.
Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68–75.CrossRefPubMed
15.
Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther. 2011;49(2):153–61.CrossRefPubMed
16.
Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520–8.CrossRefPubMed
17.
18.
Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–14.PubMedCentralCrossRefPubMed
19.
Drollmann A, Brown M, Sechaud R, et al. Effect of once-daily QVA149 on cardiac safety in healthy volunteers [abstract no. F64]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).
20.
Van de Maele B, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237. COPD patients. COPD. 2010;7(6):418–27.CrossRefPubMed
21.
Cazzola M, Calzetta L, Page CP, et al. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014;10(1):129–37.CrossRefPubMed
22.
23.
Asai K, Minakata Y, Hirata K, et al. Once-daily QVA149 is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
24.
Novartis Pharmaceuticals. Long term safety and tolerability of QVA149 versus tiotropium in Japanese patients with chronic obstructive pulmonary disease (COPD) (ARISE) [ClinicalTrials.gov identifier NCT01285492]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://​clinicaltrials.​gov/​show/​NCT01285492. Accessed 9 Oct 2013.
25.
26.
Mahler DA, Decramer M, D’Urzo AD, et al. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium In COPD patients: the BLAZE study [abstract P236 plus oral presentation]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).
27.
28.
Novartis Pharmaceuticals. Effect of QVA149 on exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) (BRIGHT) [ClinicalTrials.gov identifier NCT01294787]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://​clinicaltrials.​gov/​show/​NCT01294787. Accessed 9 Oct 2013.
29.
Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558–67.CrossRefPubMed
30.
Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnoea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
31.
Novartis Pharmaceuticals. A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate/glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD (FLAME) [ClinicalTrials.gov identifier NCT01782326]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://​clinicaltrials.​gov/​show/​NCT01782326. Accessed 9 Oct 2013.
32.
Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.CrossRefPubMed
33.
Bateman ED, Vogelmeier C, Pallante J, et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study [abstract no. 807]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).
34.
Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
35.
Vogelmeier C, Dahl R, D’Urzo A, et al. Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
36.
Barnes N, Hashimoto S, Nagase T, et al. QVA149 provides superior peak lung function in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
37.
Gallagher N, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
38.
Welte T, Dahl R, Chen H, et al. Once-daily QVA149 improves symptom scores in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
39.
Novartis Pharmaceuticals. A 26-week treatment randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 (indacaterol/glycopyrronium bromide) compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary disease [ClinicalTrials.gov identifier NCT01709903]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://​clinicaltrials.​gov/​show/​NCT01709903. Accessed 9 Oct 2013.
40.
Novartis Pharmaceuticals. Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation (RADIATE) [ClinicalTrials.gov identifier NCT01610037]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://​clinicaltrials.​gov/​show/​NCT01610037. Accessed 9 Oct 2013.
41.
Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–94.
42.
Welte T, Gallagher N, Green Y, et al. Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract no. G25]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).
43.
Bateman ED, Ferguson GT, Welte T, et al. Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol/fluticasone [abstract no. G30]. American Thoracic Society 109th international conference; 17–22 May 2013; Philadelphia (PA).
44.
Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.CrossRefPubMed
45.
Ficker J, Wedzicha JA, Decramer M, et al. QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: the SPARK study [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
46.
Banerji D, Fowler Taylor A, Kho P, et al. Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: a 52 week pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
47.
Wedzicha JA, Decramer M, Vestbo J, et al. A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
48.
49.
Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–69.CrossRefPubMed
50.
Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–5.CrossRefPubMed
51.
Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103.CrossRefPubMed
52.
53.
Welte T, Vogelmeier C, Dahl R, et al. Once-daily QVA149 has a good safety profile in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
54.
Ferguson GT, Barnes N, Mehta R, et al. Cardio- and cerebro-vascular safety of QVA149: results from a pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
55.
Chen H, D’Andrea P, Banerji D. QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: a network meta-analysis across multiple safety databases [poster]. European Respiratory Society 23rd Annual Congress; 7–11 Sep 2013; Barcelona.
56.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2014). http://​www.​goldcopd.​org/​. Accessed 30 Jan 2014.
57.
Gladysheva ES, Malhotra A, Owens RL. Influencing the decline of lung function in COPD: use of pharmacotherapy. Int J COPD. 2010;5:153–64.
58.
Lemmens V, Oenema A, Knut IK, et al. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev. 2008;17(6):535–44.CrossRefPubMed
59.
60.
Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–91.CrossRefPubMed
61.
62.
Spina D. Current and novel bronchodilators in respiratory disease. Curr Opin Pulm Med. 2014;20(1):73–86.CrossRefPubMed
63.
64.
Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2006;1(4):409–23.PubMedCentralPubMed
65.
66.
67.
Jacobsen JR, Choi SK, Combs J, et al. A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2012;22(2):1213–8.CrossRefPubMed
68.
Bateman ED, Make BJ, Nandeuil MA. Safety and tolerability of a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008;177:A653.
69.
Aparici M, Gómez-Angelats M, Vilella D, et al. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favourable safety profile in preclinical models. J Pharmacol Exp Ther. 2012;342(2):497–509.CrossRefPubMed
70.
Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477–95.CrossRefPubMed
71.
Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother. 2013;47(7–8):1017–28.CrossRefPubMed
72.
Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247–68.CrossRefPubMed
73.
Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260–70.CrossRefPubMed
74.
75.
76.
77.
Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26(1):145–55.CrossRefPubMed
78.
Pera T, Zuidhof A, Valadas J, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J. 2011;38:789–96.CrossRefPubMed
79.
Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–96.
80.
Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–41.CrossRefPubMed
81.
Roche N, Chanez P. Bronchodilator combinations for COPD: real hopes or a new Pandora’s box? Eur Respir J. 2013;42:1441–5.CrossRefPubMed
82.
Schachter EN. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc). 2013;49(7):437–46.
83.
84.
85.
Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26(3):307–17.CrossRefPubMed
86.
Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir Med. 2013;1(3):210–23.CrossRefPubMed
87.
Cyr M-C, Beauchesne M-F, Lemière C, et al. Effects of inhaled corticosteroids in monotherapy or combined with long-acting β2-agonists on mortality among patients with chronic obstructive pulmonary disease. Ann Pharmacother. 2010;44(4):613–22.CrossRefPubMed
88.
89.
90.
Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J COPD. 2012;7:73–86.
91.
Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477–95.CrossRefPubMed
92.
Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991.
93.
Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
94.
Anton E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med. 2013;7(Suppl 2):25–32.CrossRefPubMed
95.
96.
97.
Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008;133(5):1079–87.CrossRefPubMed
98.
Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. New Engl J Med. 2013;369:1491–501.CrossRefPubMed
99.
Rutten-van Mölken MP. Goossens M. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30(4):271–302.CrossRefPubMed
100.
Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax. 2008;63:962–7.CrossRefPubMed
Metadata
Title
QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease
Author
James E. Frampton
Publication date
01-03-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 4/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0194-8

Other articles of this Issue 4/2014

Drugs 4/2014 Go to the issue

Leading Article

Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer

Review Article

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis

Adis Drug Evaluation

Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes

Review Article

Spleen Tyrosine Kinase Inhibitors for Rheumatoid Arthritis: Where Are We Now?

Review Article

Interstitial Lung Disease in Patients with Rheumatoid Arthritis: Spontaneous and Drug Induced

R&D Insight Report

Tasimelteon: First Global Approval